Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


15.05.2017

1 Am J Epidemiol
1 Ann Oncol
10 Anticancer Res
1 BMC Cancer
1 Br J Cancer
1 Cancer
2 Cancer Lett
1 Cancer Res
1 Gastroenterology
1 Gut
8 Int J Cancer
2 Int J Colorectal Dis
3 Int J Oncol
1 J Clin Oncol
2 J Nucl Med
2 J Pathol
3 Oncol Rep
5 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Epidemiol

  1. TABUNG FK, Steck SE, Ma Y, Liese AD, et al
    Changes in the inflammatory potential of diet over time and risk of colorectal cancer in postmenopausal women.
    Am J Epidemiol. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. SUNAKAWA Y, Tsuji A, Fujii M, Ichikawa W, et al
    No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
    Ann Oncol. 2017 May 5. doi: 10.1093.
    PubMed     Text format    


    Anticancer Res

  3. VOGL UM, Ohler L, Rasic M, Frischer JM, et al
    Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy.
    Anticancer Res. 2017;37:1947-1955.
    PubMed     Text format     Abstract available

  4. UEDA M, Iguchi T, Masuda T, Komatsu H, et al
    Up-regulation of SLC9A9 Promotes Cancer Progression and Is Involved in Poor Prognosis in Colorectal Cancer.
    Anticancer Res. 2017;37:2255-2263.
    PubMed     Text format     Abstract available

  5. YUEH TC, Chou AK, Gong CL, Fu CK, et al
    The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan.
    Anticancer Res. 2017;37:2307-2313.
    PubMed     Text format     Abstract available

  6. SATO K, Masuda T, Hu Q, Tobo T, et al
    Phosphoserine Phosphatase Is a Novel Prognostic Biomarker on Chromosome 7 in Colorectal Cancer.
    Anticancer Res. 2017;37:2365-2371.
    PubMed     Text format     Abstract available

  7. GOMBODORJ N, Yokobori T, Yoshiyama S, Kawabata-Iwakawa R, et al
    Inhibition of Ubiquitin-conjugating Enzyme E2 May Activate the Degradation of Hypoxia-inducible Factors and, thus, Overcome Cellular Resistance to Radiation in Colorectal Cancer.
    Anticancer Res. 2017;37:2425-2436.
    PubMed     Text format     Abstract available

  8. DRESSEN K, Hermann N, Manekeller S, Walgenbach-Bruenagel G, et al
    Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.
    Anticancer Res. 2017;37:2477-2486.
    PubMed     Text format     Abstract available

  9. SASAKI S, Ueda M, Iguchi T, Kaneko M, et al
    DDR2 Expression Is Associated with a High Frequency of Peritoneal Dissemination and Poor Prognosis in Colorectal Cancer.
    Anticancer Res. 2017;37:2587-2591.
    PubMed     Text format     Abstract available

  10. IRABOR DO, Oluwasola OA, Ogunbiyi OJ, Ogun OG, et al
    Microsatellite Instability Is Common in Colorectal Cancer in Native Nigerians.
    Anticancer Res. 2017;37:2649-2654.
    PubMed     Text format     Abstract available

  11. JI WB, Um JW, Ryu JS, Hong KD, et al
    Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:2679-2682.
    PubMed     Text format     Abstract available

  12. JINGU K, Matsuo Y, Onishi H, Yamamoto T, et al
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:2709-2713.
    PubMed     Text format     Abstract available


    BMC Cancer

  13. LAMKADDEM M, Elferink MAG, Seeleman MC, Dekker E, et al
    Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study.
    BMC Cancer. 2017;17:312.
    PubMed     Text format     Abstract available


    Br J Cancer

  14. MOUNCE LTA, Price S, Valderas JM, Hamilton W, et al
    Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records.
    Br J Cancer. 2017 May 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer

  15. PARTIN MR, Gravely AA, Burgess JF Jr, Haggstrom DA, et al
    Contribution of patient, physician, and environmental factors to demographic and health variation in colonoscopy follow-up for abnormal colorectal cancer screening test results.
    Cancer. 2017 May 11. doi: 10.1002/cncr.30765.
    PubMed     Text format     Abstract available


    Cancer Lett

  16. XIANG J, Sun H, Su L, Liu L, et al
    Myocyte enhancer factor 2D promotes colorectal cancer angiogenesis downstream of hypoxia-inducible factor 1alpha.
    Cancer Lett. 2017 May 4. pii: S0304-3835(17)30309.
    PubMed     Text format     Abstract available

  17. LIN F, Zhang P, Zuo Z, Wang F, et al
    Thioredoxin-1 Promotes Colorectal Cancer Invasion and Metastasis through Crosstalk with S100P.
    Cancer Lett. 2017 May 5. pii: S0304-3835(17)30308.
    PubMed     Text format     Abstract available


    Cancer Res

  18. NIMANONG S, Ostroumov D, Wingerath J, Knocke S, et al
    CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations.
    Cancer Res. 2017;77:1918-1926.
    PubMed     Text format     Abstract available


    Gastroenterology

  19. VAN DER VLUGT M, Grobbee EJ, Bossuyt PMM, Bos A, et al
    Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    Gastroenterology. 2017 May 5. pii: S0016-5085(17)35558.
    PubMed     Text format     Abstract available


    Gut

  20. OMAR AL-HASSI H, Ng O, Brookes M
    Tumour-associated and non-tumour-associated microbiota in colorectal cancer.
    Gut. 2017 May 4. pii: gutjnl-2017-314219. doi: 10.1136/gutjnl-2017-314219.
    PubMed     Text format    


    Int J Cancer

  21. LOES IM, Immervoll H, Sorbye H, Angelsen JH, et al
    Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Int J Cancer. 2016 Mar 16. doi: 10.1002/ijc.30089.
    PubMed     Text format     Abstract available

  22. HASHIMOTO M, Kobayashi T, Tashiro H, Arihiro K, et al
    h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
    Int J Cancer. 2016;139:812-23.
    PubMed     Text format     Abstract available

  23. BEDIN C, Enzo MV, Del Bianco P, Pucciarelli S, et al
    Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
    Int J Cancer. 2017;140:1888-1898.
    PubMed     Text format     Abstract available

  24. CANAVESE M, Ngo DT, Maddern GJ, Hardingham JE, et al
    Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer.
    Int J Cancer. 2017;140:2183-2191.
    PubMed     Text format     Abstract available

  25. MODEST DP, Stintzing S, Fischer von Weikersthal L, Decker T, et al
    Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
    Int J Cancer. 2017;140:1918-1925.
    PubMed     Text format     Abstract available

  26. SNAEBJORNSSON P, Jonasson L, Olafsdottir EJ, van Grieken NCT, et al
    Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years.
    Int J Cancer. 2017 May 6. doi: 10.1002/ijc.30766.
    PubMed     Text format     Abstract available

  27. BUTT J, Werner S, Willhauck-Fleckenstein M, Michel A, et al
    Serology of Streptococcus gallolyticus subspecies gallolyticus and its association with colorectal cancer and precursors.
    Int J Cancer. 2017 May 6. doi: 10.1002/ijc.30765.
    PubMed     Text format     Abstract available

  28. BRENNER H, Niedermaier T, Chen H
    Strong subsite-specific variation in detecting advanced adenomas by fecal immunochemical testing for hemoglobin.
    Int J Cancer. 2017;140:2015-2022.
    PubMed     Text format     Abstract available


    Int J Colorectal Dis

  29. BIONDO S, Frago R, Kreisler E, Espin-Basany E, et al
    Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4).
    Int J Colorectal Dis. 2017 May 11. doi: 10.1007/s00384-017-2827.
    PubMed     Text format     Abstract available

  30. GIUSEPPE C, Antonella V
    Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases.
    Int J Colorectal Dis. 2017 May 10. doi: 10.1007/s00384-017-2831.
    PubMed     Text format     Abstract available


    Int J Oncol

  31. LI H, Li D, Meng N
    Effects of RUNX3 mediated Notch signaling pathway on biological characteristics of colorectal cancer cells.
    Int J Oncol. 2017 May 8. doi: 10.3892/ijo.2017.3988.
    PubMed     Text format     Abstract available

  32. KIM JT, Weiss HL, Evers BM
    Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells.
    Int J Oncol. 2017 May 9. doi: 10.3892/ijo.2017.3990.
    PubMed     Text format     Abstract available

  33. WANG Y, Sun N, Lu C, Bei Y, et al
    Upregulation of circadian gene 'hClock' contribution to metastasis of colorectal cancer.
    Int J Oncol. 2017 May 8. doi: 10.3892/ijo.2017.3987.
    PubMed     Text format     Abstract available


    J Clin Oncol

  34. JONES JC, Renfro LA, Al-Shamsi HO, Schrock AB, et al
    Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.
    J Clin Oncol. 2017 May 9:JCO2016714394. doi: 10.1200/JCO.2016.71.4394.
    PubMed     Text format     Abstract available


    J Nucl Med

  35. LARIMER BM, Wehrenberg-Klee E, Caraballo A, Mahmood U, et al
    Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173930.
    PubMed     Text format     Abstract available

  36. KOBASHI N, Matsumoto H, Zhao S, Meike S, et al
    The Thymidine Phosphorylase Imaging Agent 123I-IIMU Predicts the Efficacy of Capecitabine.
    J Nucl Med. 2016;57:1276-81.
    PubMed     Text format     Abstract available


    J Pathol

  37. PILATI C, Shinde J, Alexandrov LB, Assie G, et al
    Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.
    J Pathol. 2017;242:10-15.
    PubMed     Text format     Abstract available

  38. DE SMET F, Saiz Rubio M, Hompes D, Naus E, et al
    Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
    J Pathol. 2017;242:24-38.
    PubMed     Text format     Abstract available


    Oncol Rep

  39. ZHANG L, Fang Y, Feng JY, Cai QY, et al
    Chloroform fraction of Scutellaria barbata D. Don inhibits the growth of colorectal cancer cells by activating miR34a.
    Oncol Rep. 2017 May 4. doi: 10.3892/or.2017.5625.
    PubMed     Text format     Abstract available

  40. WEN L, Li Y, Jiang Z, Zhang Y, et al
    miR-944 inhibits cell migration and invasion by targeting MACC1 in colorectal cancer.
    Oncol Rep. 2017 Apr 28. doi: 10.3892/or.2017.5611.
    PubMed     Text format     Abstract available

  41. WANG Y, Lu Z, Wang N, Zhang M, et al
    MicroRNA-1299 is a negative regulator of STAT3 in colon cancer.
    Oncol Rep. 2017 Apr 26. doi: 10.3892/or.2017.5605.
    PubMed     Text format     Abstract available


    PLoS One

  42. LI Y, Li J, Liu H, Liu Y, et al
    Expression of MYSM1 is associated with tumor progression in colorectal cancer.
    PLoS One. 2017;12:e0177235.
    PubMed     Text format     Abstract available

  43. LAKATOS E, Salehi-Reyhani A, Barclay M, Stumpf MPH, et al
    Protein degradation rate is the dominant mechanism accounting for the differences in protein abundance of basal p53 in a human breast and colorectal cancer cell line.
    PLoS One. 2017;12:e0177336.
    PubMed     Text format     Abstract available


  44. Correction: Identification of a characteristic vascular belt zone in human colorectal cancer.
    PLoS One. 2017;12:e0177586.
    PubMed     Text format     Abstract available

  45. PRIETO V, Ludwig JM, Farris AB, Nagaraju GP, et al
    Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study.
    PLoS One. 2017;12:e0177212.
    PubMed     Text format     Abstract available

  46. LEE JY, Lee MK, Kim NK, Chu SH, et al
    Serum chemerin levels are independently associated with quality of life in colorectal cancer survivors: A pilot study.
    PLoS One. 2017;12:e0176929.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: